Imiquimod
Information
- Drug Name
- Imiquimod
- Description
- Entry(CIViC)
CIViC
[No Data.]
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| Strong synergistic proapoptotic effect of the Bcl-... | BCL2 | BCL2 UNDEREXPRESSION | Sensitivity | true | MMMP | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04809662 | Active, not recruiting | Comparing Immune Responses to Topical Imiquimod | March 16, 2021 | December 2022 | |
| NCT02135419 | Active, not recruiting | Phase 3 | Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions | September 24, 2014 | March 31, 2024 |
| NCT02059499 | Active, not recruiting | Phase 3 | Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions | December 28, 2015 | May 21, 2024 |
| NCT00799110 | Active, not recruiting | Phase 2 | Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod | August 2008 | December 2024 |
| NCT03276832 | Active, not recruiting | Early Phase 1 | Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma | December 20, 2017 | June 2024 |
| NCT01803152 | Active, not recruiting | Phase 1 | Dendritic Cell Vaccine for Children and Adults With Sarcoma | January 6, 2014 | July 23, 2024 |
| NCT03196180 | Active, not recruiting | Early Phase 1 | Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia | September 30, 2019 | November 4, 2024 |
| NCT00189254 | Completed | A Study to Follow up Recurrence Rates of Actinic Keratoses One Year After Completion of Study 1487-IMIQ | April 2005 | November 2005 | |
| NCT00189280 | Completed | Phase 3 | Aldara for the Treatment of Large and/or Multiple sBCC | May 2003 | October 2007 |
| NCT00189293 | Completed | Phase 4 | Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts | June 2005 | December 2007 |
| NCT00204555 | Completed | Phase 4 | Safety and Efficacy Study of Imiquimod 5% Cream Applied 3x Per Week for 8 or 12 Weeks in Low Risk Nodular Basal Cell Carcinoma | January 2002 | September 2005 |
| NCT00257530 | Completed | Phase 3 | Imiquimod Plus Antimony Immunochemotherapy for Cutaneous Leishmaniasis | December 2005 | June 2006 |
| NCT00273910 | Completed | Phase 2 | Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma | January 2006 | May 2010 |
| NCT00314756 | Completed | Phase 4 | Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage | March 2005 | November 2005 |
| NCT00453050 | Completed | Phase 1 | Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin | March 2006 | |
| NCT00504023 | Completed | N/A | Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva | April 2007 | January 2018 |
| NCT00585247 | Completed | N/A | Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks | November 2006 | August 2012 |
| NCT00674739 | Completed | Phase 3 | Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts | May 2008 | July 2009 |
| NCT00777127 | Completed | Phase 4 | Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses | December 2008 | November 2012 |
| NCT00788164 | Completed | Phase 1 | Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial Neoplasia | November 2008 | August 2023 |
| NCT00821964 | Completed | Phase 2 | Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer | December 2008 | November 29, 2012 |
| NCT00899574 | Completed | Phase 2 | Imiquimod for Breast Cancer Patients With Chest Wall Recurrence or Skin Metastases | May 2009 | June 2013 |
| NCT00941811 | Completed | Phase 2 | Immunevasion of Human Papillomavirus (HPV) in Vulvar Intraepithelial Neoplasia 2/3 and Anogenital Warts and Efficiency and Mechanisms of Imiquimod Treatment | December 2008 | May 2010 |
| NCT00948428 | Completed | Phase 3 | Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara™ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis | May 2008 | April 2009 |
| NCT00988559 | Completed | Phase 1 | Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3) | September 2009 | July 2016 |
| NCT01161888 | Completed | Phase 4 | Effect of Topical Imiquimod on Lentigo Maligna | June 2010 | March 2012 |
| NCT01171469 | Completed | Phase 1 | Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor | September 2010 | June 2012 |
| NCT01264731 | Completed | Phase 1 | Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma | January 2011 | June 2012 |
| NCT02394132 | Completed | Phase 3 | Radiotherapy or Imiquimod in Complex Lentigo Maligna | August 31, 2015 | March 30, 2023 |
| NCT00066872 | Completed | Phase 3 | Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer | October 2002 | April 2010 |
| NCT00079300 | Completed | Phase 1 | Imiquimod Cream in Treating Patients With Basal Cell Skin Cancer | January 2004 | August 2005 |
| NCT00118313 | Completed | Phase 1 | Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma | November 4, 2004 | July 28, 2006 |
| NCT00142454 | Completed | Phase 1 | NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting) | August 24, 2005 | April 25, 2006 |
| NCT00175643 | Completed | Phase 3 | Safety and Efficacy of Imiquimod Applied in Dose-Cycle for Actinic Keratoses | February 2005 | November 2005 |
| NCT00189241 | Completed | Phase 3 | A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma | February 2001 | February 2007 |
| NCT01421017 | Completed | Phase 1/Phase 2 | Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases | August 19, 2011 | August 6, 2016 |
| NCT01453179 | Completed | Phase 4 | Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA 2) | October 2011 | March 2015 |
| NCT01508884 | Completed | N/A | Intradermal Trivalent Influenza Vaccine With Imiquimod | January 2012 | December 2012 |
| NCT01593124 | Completed | Phase 2 | Identification of Novel Biomarkers of Cervicovaginal Mucosal Inflammation | May 2012 | April 2013 |
| NCT01678352 | Completed | Early Phase 1 | Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas | October 2012 | November 8, 2018 |
| NCT01808820 | Completed | Phase 1 | Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma | August 21, 2013 | July 16, 2022 |
| NCT01861535 | Completed | Phase 3 | Primary Imiquimod Treatment Versus Surgery for Vulvar Intraepithelial Neoplasia | June 2013 | February 2021 |
| NCT01909752 | Completed | Phase 2 | Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer | July 2013 | April 2017 |
| NCT01935310 | Completed | N/A | Photoaging Treatment With Imiquimod | July 2010 | August 2013 |
| NCT02052687 | Completed | Phase 1 | A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LFX453 | January 2014 | June 2014 |
| NCT02078648 | Completed | Phase 1/Phase 2 | Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme | May 2014 | January 22, 2018 |
| NCT02120898 | Completed | Phase 3 | A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic Keratoses | October 10, 2013 | April 30, 2014 |
| NCT02130323 | Completed | Phase 2/Phase 3 | Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix | February 2015 | May 9, 2017 |
| NCT02234921 | Completed | Phase 1 | Pilot Study of DRibble Vaccine for Prostate Cancer Patients | October 24, 2014 | August 15, 2018 |
| NCT02276300 | Completed | Phase 1 | HER2-Peptide Vaccination of Patients With Solid Tumors | December 2014 | July 13, 2018 |
| NCT02362152 | Completed | The Real Life Topical Field Treatment of Actinic Keratosis Study | July 2014 | December 2015 | |
| NCT02385188 | Completed | Phase 3 | Topical 5% Imiquimod Cream for Vulvar Paget's Disease | May 2015 | November 2019 |
| NCT00031759 | Completed | Phase 2 | Imiquimod in Preventing Cervical Cancer in Women With Cervical Neoplasia | June 1999 | February 2010 |
| NCT02802943 | Completed | Phase 2 | iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL | October 5, 2016 | November 18, 2022 |
| NCT02864147 | Completed | Phase 2 | Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3) | July 2016 | November 22, 2022 |
| NCT03071679 | Completed | Phase 1 | Topical Challenge With Omiganan and Imiquimod in Healthy Volunteers | February 6, 2017 | March 7, 2017 |
| NCT03233412 | Completed | Phase 2 | Randomized Clinical Trial Evaluating the Efficacy of Topical Imiquimod in High Grade Cervical Intraepithelial Lesions | January 1, 2018 | January 14, 2020 |
| NCT03472976 | Completed | Phase 1 | H5N1 With or Without Topical Aldara in Healthy Adults | June 13, 2018 | March 4, 2019 |
| NCT06356012 | Not yet recruiting | Phase 4 | Clinical Outcome and Biomarkers for Predicting Immunological Response in Patients Treated With Imiquimod | April 2, 2024 | December 31, 2028 |
| NCT05740969 | Recruiting | Phase 2 | Gene and Protein Expression Profiles After Treatment of Actinic Keratoses | February 1, 2023 | December 31, 2024 |
| NCT05468606 | Recruiting | Early Phase 1 | Coadministration of GA2 Sporozoites With Adjuvants | February 3, 2023 | December 2024 |
| NCT05838599 | Recruiting | Early Phase 1 | Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides | July 24, 2023 | February 1, 2026 |
| NCT02600949 | Recruiting | Phase 1 | Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer | May 11, 2016 | May 31, 2025 |
| NCT01795313 | Recruiting | Phase 1 | Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod | August 2012 | December 31, 2025 |
| NCT03534947 | Recruiting | Phase 2 | A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma | July 23, 2019 | June 2024 |
| NCT05405270 | Recruiting | Predicting Response In Cervical Intraepithelial Neoplasia to Topical Imiquimod Treatment | June 1, 2022 | December 2026 | |
| NCT01400672 | Terminated | Phase 1 | Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma | July 17, 2012 | October 8, 2018 |
| NCT01902771 | Terminated | Phase 1 | Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors | September 3, 2013 | January 26, 2017 |
| NCT02329171 | Terminated | Phase 3 | Imiquimod Treatment of CIN Lesions | December 2014 | June 2016 |
| NCT01403285 | Terminated | Phase 1 | Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma | August 2011 | April 2014 |
| NCT00979550 | Terminated | Phase 2 | The Effects of Aldara as an Adjunct to Laser Treatment | October 2008 | August 2013 |
| NCT01203878 | Terminated | Phase 4 | Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy | September 2010 | November 2011 |
| NCT01059110 | Terminated | Phase 4 | Comparison of Five Treatments in Patients With Plantar Warts | February 2010 | December 2016 |
| NCT00470392 | Terminated | N/A | Mechanistically-based Optimization of UV Radiation Therapy in Psoriasis | May 2007 | July 2012 |
| NCT02669459 | Unknown status | Phase 3 | Imiquimod Treatment of Residual or Recurrent CIN Lesions: a Study Protocol | May 2016 | March 2020 |
| NCT00384124 | Unknown status | Phase 2/Phase 3 | Topical Imiquimod for Bowen's Disease of the Head and Neck | November 2006 | |
| NCT05314127 | Unknown status | Phase 2 | Efficacy of Tazarotene in Treatment of Verruca Plana | April 15, 2022 | December 2022 |
| NCT02452307 | Unknown status | Phase 1/Phase 2 | Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy | April 2004 | October 2017 |
| NCT02281682 | Unknown status | Phase 4 | IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic Keratosis | November 2014 | December 2018 |
| NCT02917746 | Unknown status | N/A | Imiquimod Treatment of High-grade CIN | November 2016 | December 2020 |
| NCT01088737 | Unknown status | Phase 2/Phase 3 | Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna | January 2011 | December 2021 |
| NCT03116659 | Unknown status | Early Phase 1 | CTCL Directed Therapy | February 1, 2018 | December 30, 2020 |
| NCT01663558 | Withdrawn | Phase 4 | Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV | May 2015 | May 2016 |